Drugs / Peginterferon alfa 2a 40kDA
Peginterferon alfa 2a 40kDA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01623336 Comparator | Jan 2012 → Aug 2016 | chronic hepatitis C virus infection | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon alfa 2a 40kDA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01623336 ↗ |
| Modality | Protein / enzyme biologic | “Pegasys ® (40 kDa peginterferon alfa-2a)” NCT01623336 ↗ |
| Route | Subcutaneous | “180 micrograms, once a week, subcutaneous” NCT01623336 ↗ |